Dual GIP/GLP-1 receptor agonists Sometimes called dual agonists or twincretins, as they activate the GLP-1 receptor plus a second receptor, called GIP (glucose-dependent insulinotropic polypeptide)
Read on for the latest research on how Omadas Enhanced GLP-1 Care Track can drive favorable health outcomes and decrease financial waste
Notable anticipated approvals for third quarter 2025 include: First SC version of Keytruda in the oncology setting First treatment for non-relapsing secondary progressive multiple sclerosis An off-the shelf gene therapy for a rare genetic condition caused by human papilloma virus A first-in-class agent for bronchiectasis, a chronic inflammatory lung condition A new mechanism of action for spinal muscular atrophy A hot topic in the drug pipeline that continues to garner significant attention is GLP-1s
Commonly prescribed GLP-1 receptor agonists in the UK include semaglutide (Ozempic for diabetes
Recently, the anti-tumor effects of saffron ( Crocus sativus L.) and its bioactive components crocins, crocetin, safranal, and picrocrocin (isolated from the stigma of saffron) have been extensively explored
doi:10.1038/s41598-021-90084-y